Related Experiment Video
Updated: Jul 11, 2026
07:10
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
[Beta-blocker prescription and chronic obstructive pulmonary disease]
R Ollivier1, E Donal, P Delaval
1Département de cardiologie, hôpital Pontchaillou, CHU, 2, rue Henri-Le-Guillouxn 35033 Rennes cedex 09, France.
Annales De Cardiologie Et D'Angeiologie
|September 15, 2007
Summary
Beta-blocker prescriptions are low, especially for heart failure patients with chronic obstructive pulmonary disease (COPD). Evidence supports their safety and efficacy in COPD, necessitating improved guideline adherence for better cardiovascular care.
Area of Science:
- Cardiology
- Pulmonology
- Pharmacology
Context:
- Beta-blocker (BB) underprescription is prevalent, particularly in chronic heart failure and among patients with chronic obstructive pulmonary disease (COPD).
- Despite strong evidence supporting BB efficacy and safety, especially in the COPD context, their utilization remains suboptimal.
- This highlights a critical gap in managing cardiovascular conditions in patients with comorbid respiratory disease.
Purpose:
- To review the existing literature on beta-blocker (BB) prescription for chronic heart failure, coronary artery disease, and hypertension in patients with chronic obstructive pulmonary disease (COPD).
- To evaluate the level of evidence supporting BB use and their safety profile in COPD patients.
- To propose strategies for improving BB prescription rates in appropriate COPD patient populations.
Summary:
- This review examines the current evidence for beta-blocker (BB) use in patients with chronic obstructive pulmonary disease (COPD) who have cardiovascular conditions like chronic heart failure, coronary artery disease, and hypertension.
- The literature indicates a high level of evidence for BB efficacy and, crucially, their safety in COPD patients.
- Despite this evidence, BB prescription rates remain low in this population, indicating a need for improved clinical practice.
Impact:
- Enhancing beta-blocker (BB) prescription in eligible chronic obstructive pulmonary disease (COPD) patients can significantly improve cardiovascular outcomes.
- Addressing the underutilization of BBs in COPD patients aligns with clinical guidelines and optimizes treatment for comorbid conditions.
- This review aims to guide clinicians towards more confident and evidence-based prescribing of BBs, ultimately benefiting patient health and reducing cardiovascular morbidity.
Related Concept Videos
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...